Welcome to BioMarket Group!

Enabling Translational Medicine with BI (Technology Focus)

Additional Information

Published Date Mar 27, 2007
Special Offer No
Pages 14
PDF Fact Sheet View Fact Sheet for the report Enabling Translational Medicine with BI (Technology Focus) in PDF format.
Published on Date No
Format PDF
Publisher Datamonitor
Product Line No
Full Title No

Availability: In stock

$1,895.00

Quick Overview

This brief offers an analysis of the technology components that will enable translational research in the pharmaceutical industry.
Request free sample pages from Enabling Translational Medicine with BI (Technology Focus)

Introduction

The shift towards translational medicine depends on vendors offering technology solutions that are aligned to the unique needs of the pharmaceutical industry. BI tools, such as data analytics, must reflect domain expertise and encompass both research and development (R&D) and clinical departments of a pharmaceutical company.

Scope

  • Analyzes BI technology components, such as data integration and data analytics, for research and development in the pharmaceutical industry
  • Builds on ongoing primary research with pharmaceutical companies and technology vendors

Highlights

  • Market pressures are driving pharmaceutical firms to embrace translational medicine
  • Translational research requires BI technology components
  • BI solutions must reflect domain expertise for the drug development process; and Four technology features add value to a BI solution for translational medicine.

Reasons to Purchase

  • Align your strategy with developments in the pharmaceutical industry
  • Understand the technology features important to pharmaceutical end users
  • Gain insight into BI applications for the early stages of drug development
Request free sample pages from Enabling Translational Medicine with BI (Technology Focus)

Other selected research from the 'Business Development' category:


Impact of Counterfeits on Parallel Trade & Pharmaceutical Distribution: Issues, initiatives and insights for supply chain integrity
Parallel trade is a legitimate method of pharmaceutical import and export within the EU zone. Although previously recognized in North America as illegal, cross-border reimportation is now permitted following... Learn More


Partneringdesk Amgen, Inc. and Company Deals Briefing
Comprehensive summary of the last 5 years of deal-making by the industry’s top 50 pharmaceutical and biotech companies. Learn More